Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Valve Prosthesis Implantation | 5 | 2022 | 25 | 2.510 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2022 | 23 | 2.330 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2022 | 20 | 1.870 |
Why?
|
| Heart Neoplasms | 4 | 2021 | 12 | 1.850 |
Why?
|
| Endocarditis | 3 | 2022 | 10 | 1.740 |
Why?
|
| Postoperative Complications | 7 | 2022 | 929 | 1.120 |
Why?
|
| Endocarditis, Bacterial | 3 | 2022 | 11 | 1.050 |
Why?
|
| Humans | 39 | 2023 | 26976 | 0.860 |
Why?
|
| Cardiac Surgical Procedures | 7 | 2019 | 36 | 0.840 |
Why?
|
| Marfan Syndrome | 1 | 2023 | 4 | 0.830 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 10 | 0.800 |
Why?
|
| Aneurysm, False | 2 | 2016 | 6 | 0.790 |
Why?
|
| Heart Ventricles | 4 | 2017 | 88 | 0.770 |
Why?
|
| Pulmonary Valve | 1 | 2022 | 9 | 0.770 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2016 | 10 | 0.740 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2012 | 8 | 0.730 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 11 | 0.730 |
Why?
|
| Thymus Neoplasms | 1 | 2021 | 12 | 0.730 |
Why?
|
| Mesothelioma | 1 | 2021 | 14 | 0.730 |
Why?
|
| Stents | 2 | 2016 | 81 | 0.730 |
Why?
|
| Female | 25 | 2023 | 15196 | 0.720 |
Why?
|
| Treatment Outcome | 11 | 2022 | 3526 | 0.710 |
Why?
|
| Male | 24 | 2022 | 14756 | 0.700 |
Why?
|
| Hospital Mortality | 4 | 2020 | 141 | 0.700 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2020 | 11 | 0.700 |
Why?
|
| Heart Aneurysm | 2 | 2013 | 7 | 0.680 |
Why?
|
| Lung Diseases | 1 | 2020 | 46 | 0.680 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 35 | 0.670 |
Why?
|
| Reoperation | 4 | 2022 | 920 | 0.670 |
Why?
|
| Aortic Valve | 5 | 2020 | 24 | 0.660 |
Why?
|
| Heart Atria | 2 | 2016 | 24 | 0.640 |
Why?
|
| Vascular Surgical Procedures | 3 | 2021 | 24 | 0.630 |
Why?
|
| Coronary Artery Bypass | 4 | 2015 | 25 | 0.620 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 12 | 0.610 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 9 | 0.610 |
Why?
|
| Stroke | 1 | 2022 | 269 | 0.590 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 27 | 0.580 |
Why?
|
| Sternotomy | 2 | 2015 | 2 | 0.570 |
Why?
|
| Retrospective Studies | 11 | 2022 | 3543 | 0.560 |
Why?
|
| Middle Aged | 19 | 2021 | 9017 | 0.560 |
Why?
|
| United States | 7 | 2023 | 2029 | 0.560 |
Why?
|
| Bioprosthesis | 2 | 2017 | 6 | 0.550 |
Why?
|
| Sarcoma | 1 | 2020 | 147 | 0.550 |
Why?
|
| Adult | 12 | 2023 | 7877 | 0.530 |
Why?
|
| Endarterectomy | 1 | 2016 | 1 | 0.530 |
Why?
|
| Aged | 17 | 2021 | 9068 | 0.530 |
Why?
|
| Femoral Artery | 1 | 2016 | 5 | 0.530 |
Why?
|
| Intermittent Claudication | 1 | 2016 | 4 | 0.530 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 5 | 0.530 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 51 | 0.520 |
Why?
|
| Thoracotomy | 3 | 2015 | 30 | 0.520 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2016 | 13 | 0.510 |
Why?
|
| Cause of Death | 1 | 2016 | 65 | 0.510 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 551 | 0.510 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 32 | 0.500 |
Why?
|
| Pneumopericardium | 1 | 2015 | 1 | 0.480 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 158 | 0.470 |
Why?
|
| Cardiopulmonary Bypass | 5 | 2016 | 17 | 0.460 |
Why?
|
| Heart Failure | 2 | 2017 | 149 | 0.460 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2013 | 1 | 0.420 |
Why?
|
| Sinus of Valsalva | 1 | 2013 | 3 | 0.420 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 20 | 0.410 |
Why?
|
| Calcinosis | 1 | 2013 | 44 | 0.410 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 132 | 0.390 |
Why?
|
| Heart-Assist Devices | 1 | 2012 | 19 | 0.380 |
Why?
|
| Thoracic Arteries | 1 | 2011 | 2 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 667 | 0.360 |
Why?
|
| Hematoma | 1 | 2011 | 19 | 0.360 |
Why?
|
| Fibroma | 1 | 2011 | 5 | 0.360 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 11 | 0.350 |
Why?
|
| Hospitalization | 2 | 2023 | 310 | 0.340 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 519 | 0.320 |
Why?
|
| Risk Assessment | 3 | 2019 | 626 | 0.320 |
Why?
|
| Hemorrhage | 2 | 2020 | 82 | 0.320 |
Why?
|
| Heart Arrest, Induced | 3 | 2013 | 3 | 0.310 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 132 | 0.300 |
Why?
|
| Pericarditis | 1 | 2007 | 1 | 0.270 |
Why?
|
| Risk Factors | 4 | 2022 | 2313 | 0.240 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4833 | 0.220 |
Why?
|
| Arterioles | 3 | 2012 | 12 | 0.220 |
Why?
|
| Biopsy | 2 | 2016 | 201 | 0.210 |
Why?
|
| Postpartum Period | 1 | 2023 | 20 | 0.210 |
Why?
|
| Lower Extremity | 1 | 2022 | 39 | 0.200 |
Why?
|
| Catheterization | 1 | 2022 | 42 | 0.200 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2016 | 3 | 0.200 |
Why?
|
| Length of Stay | 2 | 2022 | 320 | 0.190 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 32 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 130 | 0.190 |
Why?
|
| Propensity Score | 1 | 2021 | 36 | 0.180 |
Why?
|
| Ischemia | 1 | 2021 | 24 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2022 | 86 | 0.180 |
Why?
|
| Acute Disease | 1 | 2021 | 176 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 165 | 0.170 |
Why?
|
| Aorta | 2 | 2021 | 17 | 0.170 |
Why?
|
| SEER Program | 1 | 2020 | 42 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 8 | 0.170 |
Why?
|
| Incidence | 1 | 2023 | 762 | 0.170 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 44 | 0.170 |
Why?
|
| Adipose Tissue | 1 | 2021 | 76 | 0.170 |
Why?
|
| Myocardium | 2 | 2013 | 100 | 0.160 |
Why?
|
| Time Factors | 4 | 2016 | 1431 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1798 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 348 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 349 | 0.160 |
Why?
|
| Young Adult | 3 | 2020 | 2016 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 46 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 364 | 0.160 |
Why?
|
| Heparin | 1 | 2019 | 21 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 132 | 0.150 |
Why?
|
| Infant | 1 | 2020 | 506 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2019 | 87 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2020 | 548 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2020 | 609 | 0.140 |
Why?
|
| Prognosis | 1 | 2020 | 804 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 121 | 0.140 |
Why?
|
| Heart Transplantation | 1 | 2017 | 30 | 0.140 |
Why?
|
| Adolescent | 2 | 2020 | 2147 | 0.140 |
Why?
|
| Graft Rejection | 1 | 2017 | 69 | 0.130 |
Why?
|
| Polyethylene Terephthalates | 1 | 2017 | 3 | 0.130 |
Why?
|
| Heart Valve Prosthesis | 1 | 2017 | 12 | 0.130 |
Why?
|
| Mitral Valve Stenosis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Heterografts | 1 | 2016 | 16 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2016 | 15 | 0.130 |
Why?
|
| Swine | 1 | 2016 | 71 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 148 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2016 | 261 | 0.130 |
Why?
|
| Time Out, Healthcare | 1 | 2016 | 1 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 176 | 0.130 |
Why?
|
| Operating Rooms | 1 | 2016 | 15 | 0.120 |
Why?
|
| Child | 1 | 2020 | 1240 | 0.120 |
Why?
|
| Checklist | 1 | 2016 | 33 | 0.120 |
Why?
|
| Tricuspid Valve | 1 | 2015 | 1 | 0.120 |
Why?
|
| Survival Rate | 2 | 2017 | 344 | 0.120 |
Why?
|
| Balloon Occlusion | 1 | 2015 | 8 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 11 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 352 | 0.120 |
Why?
|
| Foreign Bodies | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 1900 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 29 | 0.110 |
Why?
|
| Moon | 1 | 2013 | 2 | 0.110 |
Why?
|
| Heart Bypass, Left | 1 | 2013 | 1 | 0.100 |
Why?
|
| Depression | 1 | 2017 | 439 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 190 | 0.100 |
Why?
|
| Seasons | 1 | 2013 | 22 | 0.100 |
Why?
|
| Atrial Appendage | 1 | 2013 | 30 | 0.100 |
Why?
|
| Intraoperative Care | 1 | 2013 | 42 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 891 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 316 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2013 | 40 | 0.100 |
Why?
|
| Vasodilation | 1 | 2012 | 6 | 0.100 |
Why?
|
| Microcirculation | 1 | 2012 | 29 | 0.100 |
Why?
|
| Apoptosis | 1 | 2013 | 211 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2012 | 34 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 37 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2012 | 10 | 0.100 |
Why?
|
| Muscle, Skeletal | 2 | 2012 | 383 | 0.090 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 4 | 0.090 |
Why?
|
| Intercostal Muscles | 1 | 2011 | 3 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 31 | 0.090 |
Why?
|
| Thromboxane A2 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 25 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 617 | 0.090 |
Why?
|
| Muscle Contraction | 1 | 2011 | 68 | 0.090 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 7 | 0.090 |
Why?
|
| Echocardiography | 1 | 2011 | 74 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 79 | 0.080 |
Why?
|
| Animals | 1 | 2016 | 3602 | 0.080 |
Why?
|
| Fibrosis | 1 | 2007 | 31 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 73 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2007 | 73 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 9 | 0.060 |
Why?
|
| Inflammation | 2 | 2021 | 275 | 0.060 |
Why?
|
| Disease Progression | 1 | 2006 | 670 | 0.050 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2013 | 2 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2012 | 46 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2021 | 21 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 52 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 75 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 67 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 31 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 24 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 143 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2021 | 55 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 175 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 146 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 14 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 304 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 54 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 82 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 218 | 0.030 |
Why?
|
| Systems Theory | 1 | 2016 | 3 | 0.030 |
Why?
|
| Medication Errors | 1 | 2016 | 11 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 26 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2016 | 22 | 0.030 |
Why?
|
| Medical Errors | 1 | 2016 | 26 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 36 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2016 | 135 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 109 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 483 | 0.030 |
Why?
|
| Cardioplegic Solutions | 1 | 2013 | 1 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 12 | 0.030 |
Why?
|
| Rhode Island | 1 | 2013 | 2 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 36 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 28 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 118 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2012 | 4 | 0.020 |
Why?
|
| Nitroprusside | 1 | 2012 | 6 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2012 | 19 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2012 | 16 | 0.020 |
Why?
|
| Substance P | 1 | 2012 | 11 | 0.020 |
Why?
|
| Tyrosine | 1 | 2012 | 23 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2012 | 8 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2012 | 8 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 247 | 0.020 |
Why?
|
| Chicago | 1 | 2016 | 936 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 36 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 39 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 274 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 31 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 146 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2012 | 48 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 394 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 331 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 70 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 411 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 60 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 462 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 199 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 272 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 588 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 558 | 0.020 |
Why?
|